Reference:
  1. Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resisitant hepatitis B mutants strongly affects viral replication. Hepatology. 2002; 36:507–508.
  2. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007; 21:1273–1281.
  3. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis.  2002;40:1331–3
  4. J. Borrás-Blasco, A. Navarro-Ruiz, C. Borrás, E. Casterá. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection.Journal of Antimicrobial Chemotherapy , Volume 62, Issue 5, November 2008,879–888
  5. Staszewiski S, Gallant J, Pozniak AL, Sulieman JMAH, De Jesus E, Koenig E, et al . Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. In: Program and abstracts of the XIVth International AIDS Conference . Barcelona, Spain, 7–12 July 2002.
  6. Calabrese LH, Michel BA, Bloch dA, Arend WP, Edworthy SM, Fauci AS, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990 Aug;33(8):1108-1113.
  7. Sais G, Vidaller A, Jucglà A, Gallardo F, Peyrí J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch dermatol 1995 dec;131(12):1399-1402.
  8. Said A. Al-Busafi, Abdulatif Al-Suleimani, Aysha Al-Hamadani and Wasif Rasool Tenofovir-induced Leukocytoclastic Vasculitis. Oman Medical Journal.2017;32(5):429-431.
  9. Solay AH, Eser FC, Tutuncu EE, Gencler B, Onder EO. A Leukocytoclastic Vasculitis Case Due to Tenofovir Use. Journal of Clinical and Analytical Medicine.2017;8 (suppl 3):187-191.
  10. WoolleyIJ, VeitchAJ, HarangozoCS, MoyleM, KormanTM. Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient. AIDS. 2004; 18:1857–1858.
  11. Virath R, Balai M, Gupta LK. Blaschkoid Lichenoid Drug Eruption Due to Tenofovir. Indian Dermatol Online J . 2020;11(5):826-827.
  12. Pankaj Jain.A Case of Cutaneous Reaction with Tenofovir Disoproxil Fumarate. Journal of clinical and experimental hepatology. 2013;3(3):254-255.
  13. Lockhart SM, Rathbun RC, Stephens JR, Baker DL, Drevets DA, Greenfield RA, et al. Cutaneous reactions with tenofovir disoproxil fumarate: A report of nine cases. AIDS.  2007; 21:1370–3
  14. Obadah Aqtash, Aman Naim Ajmeri, Brent A Thornhill, Elise Anderson and et. al. A unique case of tenofovir induced DRESS Syndrome associated with Raynaud’s of the tongue. International Journal of General Medicine 2019:12 .
  15. Verma R, Vasudevan B, Shankar S, Pragasam V, Suwal B, Venugopal R. First reported case of tenofovir-induced photoallergic reaction. Indian J Pharmacol.  2012; 44:651–3.
  16. Khanijao Suchit, Kitchloo Karishma, Kamath Anisha, Dancy Leah and et. al. Tenofovir-induced bullous lesions. Allergy and airway. 2016;150(4)